Yutaka Niihara

All filings by Yutaka Niihara on record concern Emmaus Life Sciences, Inc., in the capacity of chief executive. Over a trading history stretching from 31 May 2013 to 30 November 2022, the count stands at 379 filings.

In open-market terms, that means 373 purchases worth €2.3M on one side and 1 sale on the other. No amount is published for 1 filing, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 1 share grant and 2 option exercises. Since January 2022: 56 purchases and no sales on the market.

A typical purchase (the median) is worth €2,587. On 34 out of 138 purchases, another insider of the same company was buying within the same 30 days. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. Ninety days after publication, 138 purchases show a median change of -6.1%, with the price up in 36% of them. Past outcomes like these are no guarantee of what comes next.

On 1 December 2022 came the latest disclosure, an open-market purchase for €1,688 in Emmaus Life Sciences, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.